BR112021017436A2 - Composições farmacêuticas para tratamento de doenças ou transtornos oculares - Google Patents
Composições farmacêuticas para tratamento de doenças ou transtornos ocularesInfo
- Publication number
- BR112021017436A2 BR112021017436A2 BR112021017436A BR112021017436A BR112021017436A2 BR 112021017436 A2 BR112021017436 A2 BR 112021017436A2 BR 112021017436 A BR112021017436 A BR 112021017436A BR 112021017436 A BR112021017436 A BR 112021017436A BR 112021017436 A2 BR112021017436 A2 BR 112021017436A2
- Authority
- BR
- Brazil
- Prior art keywords
- pharmaceutical compositions
- disorders
- ocular diseases
- treating ocular
- released
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/472—Non-condensed isoquinolines, e.g. papaverine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/30—Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
- A61K47/34—Macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyesters, polyamino acids, polysiloxanes, polyphosphazines, copolymers of polyalkylene glycol or poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
- A61K9/0024—Solid, semi-solid or solidifying implants, which are implanted or injected in body tissue
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
- A61K31/52—Purines, e.g. adenine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/55—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
- A61K31/551—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole having two nitrogen atoms, e.g. dilazep
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
- A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
- A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
- A61K9/0051—Ocular inserts or implants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0048—Eye, e.g. artificial tears
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Ophthalmology & Optometry (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Inorganic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Organic Chemistry (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Dermatology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicinal Preparation (AREA)
- Materials For Medical Uses (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Polyamides (AREA)
- Compositions Of Macromolecular Compounds (AREA)
- Biological Depolymerization Polymers (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201962814198P | 2019-03-05 | 2019-03-05 | |
| PCT/US2020/021136 WO2020181060A1 (en) | 2019-03-05 | 2020-03-05 | Pharmaceutical compositions for treating ocular diseases or disorders |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| BR112021017436A2 true BR112021017436A2 (pt) | 2021-11-16 |
Family
ID=72337143
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| BR112021017436A BR112021017436A2 (pt) | 2019-03-05 | 2020-03-05 | Composições farmacêuticas para tratamento de doenças ou transtornos oculares |
Country Status (10)
| Country | Link |
|---|---|
| US (2) | US12478577B2 (https=) |
| EP (1) | EP3934646A4 (https=) |
| JP (2) | JP7570342B2 (https=) |
| KR (1) | KR20210135560A (https=) |
| CN (3) | CN118304422A (https=) |
| AU (1) | AU2020232314C1 (https=) |
| BR (1) | BR112021017436A2 (https=) |
| CA (1) | CA3132635A1 (https=) |
| MX (2) | MX2021010599A (https=) |
| WO (1) | WO2020181060A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX2021010599A (es) | 2019-03-05 | 2021-12-10 | Aerie Pharmaceuticals Inc | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. |
| CA3166738A1 (en) | 2020-02-06 | 2021-08-12 | Charles D. Blizzard | Travoprost compositions and methods for treating ocular diseases |
| EP3884929B1 (en) | 2020-03-25 | 2023-06-14 | Ocular Therapeutix, Inc. | Ocular implant containing a tyrosine kinase inhibitor |
| WO2021207486A1 (en) * | 2020-04-08 | 2021-10-14 | Aerie Pharmaceuticals, Inc. | Treatments |
| CA3218251A1 (en) | 2021-04-30 | 2022-11-03 | Perfuse Therapeutics, Inc. | Pharmaceutical compositions and intravitreal drug delivery systems for the treatment of ocular diseases |
| WO2022235906A1 (en) | 2021-05-05 | 2022-11-10 | Aerie Pharmaceuticals, Inc. | Pharmaceutical preparation |
| CN120897764A (zh) | 2023-04-11 | 2025-11-04 | 视尔普斯眼科公司 | 包含阿西替尼多晶型物iv的眼部植入物 |
| WO2025146683A1 (en) | 2024-01-03 | 2025-07-10 | Lyotropic Delivery Systems Ltd. | Topical formulations for delivery of an active compound to the back of the eye |
| WO2025169089A1 (en) | 2024-02-05 | 2025-08-14 | Sun Pharmaceutical Industries Limited | Ophthalmic compositions of tyrosine kinase inhibitors and their uses |
Family Cites Families (22)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2649672C (en) * | 2006-05-02 | 2015-07-07 | Medivas, Llc | Delivery of ophthalmologic agents to the exterior or interior of the eye |
| JP2011518812A (ja) * | 2008-04-25 | 2011-06-30 | ディーエスエム アイピー アセッツ ビー．ブイ． | チオエステル結合を有するポリマーを含む粒子 |
| US9095506B2 (en) | 2008-11-17 | 2015-08-04 | Allergan, Inc. | Biodegradable alpha-2 agonist polymeric implants and therapeutic uses thereof |
| EP2587304B1 (en) * | 2010-06-22 | 2019-12-18 | Toyobo Co., Ltd. | Liquid crystal display device, polarizer and protective film |
| BR112013018739A2 (pt) * | 2010-12-29 | 2019-09-24 | Jade Therapeutics Inc | sistema de distribuição de medicamento ocular |
| JP6135870B2 (ja) * | 2011-05-02 | 2017-05-31 | ディーエスエム アイピー アセッツ ビー．ブイ． | 生分解性ポリマーを含む繊維 |
| WO2012150255A1 (en) * | 2011-05-02 | 2012-11-08 | Dsm Ip Assets B.V. | Bis-(alpha-amino-diol-diester) containing polyesteramide for ophtamology |
| US20150037422A1 (en) * | 2012-02-22 | 2015-02-05 | Trustees Of Tufts College | Compositions and methods for ocular delivery of a therapeutic agent |
| CA2881729C (en) | 2012-10-02 | 2021-05-04 | Dsm Ip Assets B.V. | Drug delivery composition comprising proteins and biodegradable polyesteramides |
| EP3702394B1 (en) * | 2012-10-24 | 2023-11-22 | DSM IP Assets B.V. | Fibers comprising polyesteramide copolymers for drug delivery |
| CN109602691A (zh) * | 2013-02-15 | 2019-04-12 | 阿勒根公司 | 持续药物递送植入物 |
| ES2834964T3 (es) * | 2013-04-01 | 2021-06-21 | Allergan Inc | Sistema de administración de fármacos mediante microesferas para liberación intraocular sostenida |
| WO2015126477A1 (en) | 2013-11-08 | 2015-08-27 | Tyrx, Inc. | Polymeric drug delivery system for treating surgical complications |
| MX2016007345A (es) * | 2013-12-06 | 2016-12-09 | Envisia Therapeutics Inc | Implante intracameral para el tratamiento de una condicion ocular. |
| WO2015095772A2 (en) * | 2013-12-20 | 2015-06-25 | Emory University | Formulations and methods for targeted ocular delivery of therapeutic agents |
| CN109481447A (zh) * | 2014-09-06 | 2019-03-19 | 整体生物系统有限责任公司 | 用于在眼中实现持续药物释放的方法和生物相容性组合物 |
| EP3233067B1 (en) * | 2014-12-18 | 2019-11-06 | DSM IP Assets B.V. | Drug delivery system for delivery of acid sensitive drugs |
| EP3324944A4 (en) | 2015-07-23 | 2019-04-03 | Aerie Pharmaceuticals, Inc. | INTRAVITREAL AGGREGATION SYSTEMS FOR THE TREATMENT OF EYE DISEASE |
| WO2017120600A1 (en) | 2016-01-08 | 2017-07-13 | Clearside Biomedical, Inc. | Compositions and methods of treating wet age-related macular degeneration |
| US20180117148A1 (en) * | 2016-10-28 | 2018-05-03 | Andrew J. Holman | Compounds, pharmaceutical compositions and methods of treatments of immune related diseases and disorders |
| WO2018161035A1 (en) * | 2017-03-03 | 2018-09-07 | Macregen, Inc. | Treatment of age-related macular degeneration and other eye diseases with one or more therapeutic agents |
| MX2021010599A (es) | 2019-03-05 | 2021-12-10 | Aerie Pharmaceuticals Inc | Composiciones farmaceuticas para el tratamiento de enfermedades o trastornos oculares. |
-
2020
- 2020-03-05 MX MX2021010599A patent/MX2021010599A/es unknown
- 2020-03-05 WO PCT/US2020/021136 patent/WO2020181060A1/en not_active Ceased
- 2020-03-05 CN CN202410368231.1A patent/CN118304422A/zh active Pending
- 2020-03-05 BR BR112021017436A patent/BR112021017436A2/pt unknown
- 2020-03-05 JP JP2021552571A patent/JP7570342B2/ja active Active
- 2020-03-05 KR KR1020217031760A patent/KR20210135560A/ko active Pending
- 2020-03-05 EP EP20766052.3A patent/EP3934646A4/en active Pending
- 2020-03-05 CN CN202410368463.7A patent/CN118286445A/zh active Pending
- 2020-03-05 CA CA3132635A patent/CA3132635A1/en active Pending
- 2020-03-05 US US16/810,149 patent/US12478577B2/en active Active
- 2020-03-05 CN CN202080033265.5A patent/CN113784727B/zh active Active
- 2020-03-05 AU AU2020232314A patent/AU2020232314C1/en active Active
-
2021
- 2021-09-02 MX MX2025002265A patent/MX2025002265A/es unknown
-
2024
- 2024-10-08 JP JP2024176401A patent/JP7838047B2/ja active Active
-
2025
- 2025-10-10 US US19/355,788 patent/US20260034056A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| KR20210135560A (ko) | 2021-11-15 |
| MX2025002265A (es) | 2025-04-02 |
| CN118286445A (zh) | 2024-07-05 |
| CN118304422A (zh) | 2024-07-09 |
| AU2020232314C1 (en) | 2024-03-28 |
| JP2022523548A (ja) | 2022-04-25 |
| AU2020232314A1 (en) | 2021-09-30 |
| AU2020232314B2 (en) | 2023-10-12 |
| CN113784727A (zh) | 2021-12-10 |
| JP7838047B2 (ja) | 2026-03-31 |
| US20260034056A1 (en) | 2026-02-05 |
| CA3132635A1 (en) | 2020-09-10 |
| JP2025004160A (ja) | 2025-01-14 |
| JP7570342B2 (ja) | 2024-10-21 |
| JP2025004161A (ja) | 2025-01-14 |
| US20200306182A1 (en) | 2020-10-01 |
| EP3934646A1 (en) | 2022-01-12 |
| US12478577B2 (en) | 2025-11-25 |
| WO2020181060A1 (en) | 2020-09-10 |
| MX2021010599A (es) | 2021-12-10 |
| CN113784727B (zh) | 2024-03-29 |
| EP3934646A4 (en) | 2022-12-14 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| BR112021017436A2 (pt) | Composições farmacêuticas para tratamento de doenças ou transtornos oculares | |
| EP4491229A3 (en) | Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases | |
| MX388385B (es) | Composiciones que comprenden tacrolimus para el tratamiento de enfermedades inflamatorias intraoculares. | |
| BR112018068906A2 (pt) | composição, método, método de redução de risco, prevenção ou tratamento de um indivíduo que tem uma doença ou distúrbio autoimune, método de indução de degradação de uma proteína-alvo numa célula, método para reduzir o risco, prevenir ou tratar um estado da doença ou afecção num paciente em que a atividade proteica desregulada é responsável pelo referido estado da doença ou afecção, método para reduzir o risco, prevenir ou tratar câncer num indivíduo e método de tratamento de uma doença ou distúrbio genético num indivíduo | |
| BR112017017448A2 (pt) | métodos e composições para o tratamento de doença do olho ressecado e outros distúrbios do olho | |
| BR112018008358A2 (pt) | ?composições e métodos para terapia relacionada à microbiota fecal? | |
| BR112018017172A2 (pt) | anticorpos monoclonais anti-alfa-sinucleína para prevenção da agregação de tau | |
| BR112017015059A2 (pt) | inibidor de proteassoma e uso | |
| BR112016025312A2 (pt) | variantes de anticorpo, anticorpo anti-fator d, formulação farmacêutica, dispositivo de distribuição, utilização da formulação e de uma composição, composição e método de tratamento de uma desordem | |
| UY30097A1 (es) | Usos terapeuticos de inhibidores de rtp801 | |
| PH12021550605A1 (en) | Farnesoid x receptor agonists and uses thereof | |
| BR112017020948A2 (pt) | composição farmacêutica, método para preparar um agente, método para tratar uma doença ocular e uso de uma proteína de fusão | |
| CO2022007814A2 (es) | Ligandos de la pseudoquinasa tyk2 | |
| BR112022000855A2 (pt) | Moduladores de nlrp3 | |
| ZA202000375B (en) | Compounds for the prevention and treatment of medical disorders and uses thereof | |
| BR112021019070A2 (pt) | Ligantes de pseudoquinase tyk2 | |
| MX2021011507A (es) | Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento. | |
| JOP20220259A1 (ar) | تركيبات تشتمل على جسيمات نانونية، طريقة تصنيعها واستخدامها | |
| MX2022000646A (es) | Derivados de n-((1,2,3,5,6,7-hexahidro-s-indacen-4-il)carbamoil)-4 ,5,6,7- tetrahidrobenzofuran-2-sulfonamida y compuestos relacionados como moduladores de nlpr3 para el tratamiento de esclerosis múltiple (ms). | |
| MX2021008941A (es) | Moduladores gpr35. | |
| EP3606570B8 (en) | Collagen peptide-based medicament compositions for use in the treatment of ocular diseases, disorders or wounds | |
| CO2022014499A2 (es) | Moduladores de nlrp3 | |
| BR112017008805A2 (pt) | tratamento de córnea usando laminina | |
| BR112017006406A2 (pt) | composições e métodos para o tratamento e profilaxia de infecções de sítio cirúrgico | |
| CO2019002245A2 (es) | Combinación de agonistas de fxr |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| B06W | Patent application suspended after preliminary examination (for patents with searches from other patent authorities) chapter 6.23 patent gazette] | ||
| B25A | Requested transfer of rights approved |
Owner name: ALCON INC. (CH) |